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Background: Prone positioning for breast radiotherapy is preferable when the aim is a 
 reduction of the dose to the ipsilateral lung or the heart in certain left-sided cases.
Materials and methods: In 100 breast cancer cases awaiting postoperative whole-breast 
radiotherapy, conformal radiotherapy plans were prospectively generated in both prone and 
supine positions. The axillary nodal region (levels I–III) and internal mammary (IM) lymph-node 
region in the upper three intercostal spaces were retrospectively contoured. The mean doses 
to the nodal regions and the volume receiving 25 Gy (V
25Gy
), V
45Gy
, and V
47.5Gy
 were compared 
between the two treatment positions.
Results: In most cases, the doses to axillary levels I–III and the IM lymph nodes were inadequate, 
regardless of the treatment position. The nodal doses were significantly lower in the prone than 
in the supine position. The radiation doses to levels II–III and IM nodes were especially low. 
The V
45Gy
 and V
47.5Gy
 of the level I axillary lymph nodes were 54.6% and 40.2%, respectively, 
in the supine, and 3.0% and 1.7%, respectively, in the prone position. In the supine position, 
only 17 patients (17%) received a mean dose of 45 Gy to the axillary level I nodes.
Conclusion: The radiation dose to the axillary and IM lymph nodes during breast radiotherapy 
is therapeutically insufficient in most cases, and is significantly lower in the prone position than 
in the supine position.
Keywords: axillary lymph nodes, breast radiotherapy, internal mammary nodes, prone 
 positioning, supine positioning
Background
Prone breast radiotherapy is being increasingly utilized in consequence of its  favorable 
effects on the dose to the organs at risk (OARs), such as the ipsilateral lung and the 
heart in left-sided cases.1–5 All patients with right-sided breast cancer benefit from 
prone positioning because of the dramatic reduction in the ipsilateral lung dose, and 
at least 60% of patients with left-sided breast cancer benefit from lower dose to the 
heart and/or left anterior descending coronary artery.1–3,5 Prone breast radiotherapy has 
proved feasible, and may be performed with good repositioning accuracy.3,6,7 Breast 
radiotherapy in either the prone or the supine position ensures good coverage of the 
operated breast, and similar dose homogeneity.3,4,8 Prone breast radiotherapy provides 
a long-term outcome (local/regional control and toxicity) similar to that of treatment 
in the supine position.9
The radiotherapy of regional lymph nodes contributes to improved relapse-free and 
overall survival in patients with axillary lymph node-positive breast cancer.10–12 The 
extent of survival benefit has been found by the Danish Breast Cancer Group to be 
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similar in one to three and four or more lymph node-positive 
cases.12 In sentinel lymph node-positive patients, the role of 
radiotherapy has not been fully clarified. The noninferior-
ity of whole-breast radiotherapy versus complete axillary 
block dissection plus breast radiotherapy in cases with one 
to two positive sentinel lymph nodes was demonstrated in the 
American College of Surgeons Oncology Group ( ACOSOG) 
Z0011 trial.13 Equal local and regional control rates have 
been ascribed to the irradiation of the level I axillary lymph 
nodes,13,14 though no solid data exist as yet to support this 
hypothesis. The extent to which the patients in the ACOSOG 
study13 received nodal radiotherapy is currently undergoing 
retrospective evaluation. The management of internal mam-
mary (IM) nodes is controversial.15 In axillary node-positive 
cases, the risk of IM-node involvement increases signifi-
cantly with the number of positive lymph nodes. The role 
of IM nodal irradiation in these high-risk patients, however, 
is still a subject of ongoing large randomized multicenter 
(European Organisation for Research and Treatment of 
Cancer [EORTC] and National Cancer Institute of Canada 
[NCIC]) trials.16,17 Approximately a quarter of the sentinel 
nodes are located in the IM chain, but their routine removal 
is not widely practised.18 Elective irradiation of the IM chain 
after sentinel biopsy may seem justified in rare cases.19,20 As 
the need to irradiate the nodal regions varies individually, 
careful control of the nodal dose is important in each case. 
A number of research groups have demonstrated that the dose 
to the axillary or sentinel lymph-node areas during supine 
breast irradiation with tangential fields is usually insufficient 
“therapeutically”.21–26 In the prone position, the axillary nodal 
doses are further decreased.21,22
In this retrospective study, the goal was to analyze the 
radiation dose to the nodal regions, including the axillary 
and IM nodes, in a large set of 3-D conformal radiotherapy 
plans generated for whole-breast irradiation in either the 
prone or supine position.
Materials and methods
This retrospective study was based on the 3-D conformal 
radiotherapy plans of 100 consecutive breast cancer patients 
requiring radiotherapy of the operated breast. The patients 
had been included in a clinical study approved by the 
Institutional Review Board of the University of Szeged to 
investigate the effects of patient-related anatomic features 
on optimal positioning (prone versus supine) in left-sided 
breast cancer.4
All relevant technical details have been published 
previously.3,4 Briefly, computed tomography (CT) images 
were acquired at 0.5 cm intervals throughout the entire plan-
ning volume. The target volume and OARs were contoured 
on the CT slices in the radiotherapy-planning system. The 
clinical target volume (operated breast) was contoured at the 
chest wall: breast parenchyma interface, 4 mm from the skin, 
cranially from the head of the clavicle, medially from the bor-
der of the sternum, and laterally and caudally from where the 
visible breast parenchyma and connective tissue verge. 3-D 
image reconstruction was used to check delineation. Planning 
target volumes (PTVs) were generated as described in Varga 
et al.4 The level I–III axillary and ipsilateral IM lymph-node 
regions were retrospectively contoured according to the 
Radiation Therapy Oncology Group (RTOG) contouring 
atlas,27 as shown in Figure 1. IM nodes were contoured in 
the upper three intercostal spaces, with typically 18 slices 
being taken. The aim in either setup was equivalent target 
and nodal volume contouring.
CT-based 3-D treatment planning (XIO® version 4.2.0 
convolution algorithm for photon-dose calculation; Elekta, 
Stockholm, Sweden) was performed in both the supine and 
prone positions, as detailed previously.3,4 Treatment plans 
were developed by applying conventional 6 MV tangential 
photon fields set up isocentrically, and a median of two 
(one to three) individually weighted 6/15 MV segmental 
fields superimposed on the tangential fields by using a 
multileaf collimator. All plans were generated by the same 
physicist (ZV) with the intent of ensuring similar coverage 
and dose homogeneity. A mean dose to the PTV of 50 Gy 
was aimed for.
Figure 1 (A and B) left-sided whole-breast irradiation. (A) Beam’s eye view of 
the right anterior oblique field, with 3-D reconstruction of axillary levels I–III and 
internal mammary lymph-node regions in the prone and supine positions. (B) Typical 
field arrangements and their relation to the node regions.
 
Th
er
ap
eu
tic
s 
an
d 
Cl
in
ica
l R
isk
 M
an
ag
em
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
16
0.
11
4.
10
6.
12
7 
on
 2
9-
Au
g-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Therapeutics and Clinical Risk Management 2014:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
369
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For analysis of the dose distribution, the volume receiving 
95%–107% of the total dose (V
95%–107%
), the doses received 
by 5% and 95% of the PTV (D
5%
/D
95%
), and the conformation 
number were calculated using the following equation:
 Conformation number =
TV
TV
TV
V
RI RI
RI
×  (1)
where TV is target volume, ie, PTV, TV
RI
 is the target 
volume covered by the reference isodose, and V
RI
 is the 
volume of the reference isodose.28
As regards the doses to the individual nodal regions, 
the mean doses and the volumes receiving .25 Gy 
(V
25Gy
), .45 Gy (V
45Gy
), and .47.5 Gy (V
47.5Gy
) were evalu-
ated retrospectively. For the analysis of the relation between 
the anatomical features of the patient and dose to nodal 
regions, the PTV, body mass index (BMI), volume of level 
I axillary lymph-node region, and breast separation3 were 
registered. The mean dose, V
25Gy
, V
45Gy
, and V
47.5Gy
 of axillary 
level I and the homogeneity and conformity indices of the 
target volumes were compared in the prone versus supine 
position by using paired-sample t-tests.
Results
One hundred pairs of treatment plans were analyzed. The 
volumes of the treated breast, axillary levels I–III, and IM 
nodes are indicated in Table 1. No significant differences in 
the respective volumes were found between the prone and 
supine positions. The dose homogeneity within the PTV 
was better in the supine position: V
95%–107%
 mean ± standard 
error was 89.08%±0.14% versus 91.92%±0.18% in 
the prone  versus supine position (P,0.001); D
5%
/D
95%
 
(mean ± standard error) was 1.17±0.01 versus 1.13±0.01 
in the prone versus supine position. Doses to the OARs 
were similar to those published previously for the whole 
study population.4
In most cases, doses to axillary levels I–III and the IM 
lymph nodes were insufficient, regardless of the treatment 
position. The doses were significantly lower in the prone 
than in the supine position (Tables 2 and 3). The radiation 
doses to levels II and III and the IM nodes were especially 
low. The V
45Gy
 and V
47.5Gy
 of the level I axillary lymph nodes 
were 54.6% and 40.2%, respectively, in the supine, and 3.0% 
and 1.7%, respectively, in the prone position. The number of 
patients who received a mean dose of $45 Gy to the level I 
axillary lymph nodes in the supine position was 17 (17%). 
No difference was found in the anatomical features of 
those whose axillary level I dose was higher or lower than 
45 Gy (PTV, 1,073.3 versus 945.5 cm3; BMI, 28.6 versus 
28.1 kg/m2; volume of level I axillary lymph-node region, 
63.3 versus 62.5 cm3; breast separation, 22.3 versus 21.4 cm; 
 respectively). None of the patients received $45 Gy to the 
other lymph-node regions.
Discussion
Our results clearly reveal that the radiation dose to the axil-
lary and IM lymph nodes during whole-breast irradiation is 
therapeutically insufficient in most cases, and is significantly 
lower in the prone position than in the supine position.
In certain situations, such as sentinel and/or axillary 
lymph-node and lymphovascular invasion negativity, 
 irradiation of the lymph-node areas may obviously be 
neglected. In other cases, however, the benefit of complete 
or partial nodal irradiation should be considered. In senti-
nel lymph node-positive cases, the probability that further 
positive regional lymph nodes are present varies with the 
nature of the primary tumor (size, grade, hormone-receptor 
status, and the presence of multifocality or lymphovascular 
invasion) and the number/rate of positive sentinel nodes. 
Nomograms utilizing the aforementioned tumor-related data 
are available for estimation of the involvement of the axil-
lary lymph nodes.29 Rarely, the lymph-node status remains 
unknown. If the risk of axillary lymph-node positivity 
Table 1 Volumes of the irradiated breast (PTV) and the nodal 
regions in the prone and supine positions
Volumes Prone (mean ± SE, 
mm3)
Supine (mean ± SE, 
mm3)
P (paired 
t-test)
PTV 971.6±44.0 967.3±44.4 0.380
level i 61.6±2.0 62.7±2.2 0.306
level ii 14.2±0.4 13.9±1.2 0.792
level iii 6.0±0.2 5.9±0.2 0.451
iM 4.7±0.1 4.7±0.1 0.450
Note: The volumes of the PTV or the nodal regions did not differ in the prone 
versus the supine position.
Abbreviations: PTV, planning target volume; se, standard error; iM, internal 
mammary.
Table 2 Mean doses to the nodal regions in the prone and supine 
positions
Volumes Mean dose ± SE, Gy (range) P (paired 
t-test)Prone Supine
level i 6.6±0.6 (0.6–29.8) 37.7±0.7 (18.6–50.5) ,0.001
level ii 2.1±0.4 (0.6–30.4) 13.8±0.1 (0.7–45.8) ,0.001
level iii 0.5±0.1 (0.1–6.2) 1.6±0.2 (0.3–12.6) ,0.001
iM 6.2±0.6 (1.4–48.9) 15.3±6.2 (2.6–38.7) ,0.001
Note: The mean doses to axillary levels i–iii and the internal mammary (iM) lymph 
nodes were significantly lower in the prone position than in the supine position.
Abbreviation: se, standard error.
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is high,  complementary local treatment, such as axillary 
block dissection or regional irradiation, is justified in order 
to eradicate persistent regional disease. In such cases, an 
individualized approach has been suggested, with the iden-
tification and irradiation of different target volumes (axillary 
levels I–III and supraclavicular lymph nodes) in accordance 
with the risk of their involvement.14 Sentinel lymph nodes 
are present in the IM region in about 20%–30% of cases, 
but their routine biopsy is not justified. If they become 
positive, radiotherapy of the IM region appears reasonable, 
but this approach (which certainly increases the lung and 
heart doses in left-sided cases) has not yet been validated 
in clinical practice. The results of the present study and 
other analyses21–26 demonstrate that when irradiation of any 
of the axillary lymph-node levels or the IM lymph nodes 
is required, special attention should be paid to the doses 
to these target volumes; in most cases, the conventional 
tangential fields must be modified to meet the dosimetric 
need. Although prone radiotherapy is traditionally limited 
to the operated breast, efforts have been made to extend 
prone radiotherapy to patients who need irradiation of the 
axillary and supraclavicular lymph-node regions, through 
the use of conformal radiotherapy,30 helical tomotherapy,31 or 
intensity-modulated radiation therapy.32 Therefore, in order 
to maintain the advantages of prone positioning, the target 
volume could be extended to the lymph nodes; nevertheless, 
the feasibility and repositioning accuracy of the method need 
to be investigated.
In our study, nodal regions were contoured with regard 
to their anatomical boundaries based on the RTOG atlas.27 In 
the supine position, around half of the axillary level I volume 
was exposed to 45 Gy on average, and the irradiation of 
such a significant part harboring residual disease may well 
be of clinical significance; this is obviously not the case if 
radiotherapy is performed in the prone position.
Our findings are consistent with those of two other con-
formal radiotherapy studies that compared doses to the three 
axillary lymph-node levels in the prone versus the supine posi-
tion during whole-breast irradiation.21,22  Alonso-Basanta et al 
studied the radiation-treatment plans (prone or supine) of 20 
patients,21 and Leonard et al compared the plans for 23 patients 
in the prone and 23 patients in the supine  position.22 Both stud-
ies led to the conclusion that the coverage of the three axillary 
nodal levels was inadequate in either position, but the doses 
were even lower in the prone than in the supine position. Our 
study on 100 patients provides additional information indicat-
ing that breast radiotherapy does not provide relevant coverage 
of the IM nodes in either the prone or the supine position.
In the prone position, the geography of the breast and the 
chest wall changes, and the conformity of the treatment plan 
is improved as less volume is irradiated outside the PTV.4 
In fact, not only are the conventionally identified OARs 
better spared from irradiation, but the volumes containing 
the regional lymph nodes are nearly completely excluded 
from the irradiated volume. While we found a mean dose 
of 45 Gy to the level I axillary lymph nodes in 17% of the 
patients in the supine position, none of the patients in the 
prone position received a relevant dose to any of the regional 
lymph nodes. The difference of nodal coverage between the 
two positions should be considered, since the irradiation of 
the regional lymph nodes may be individually beneficial or 
 unnecessary. The supine position should be preferred, and the 
dose to the level I axillary nodes should be carefully checked 
if its therapeutic irradiation is an aim. Due to the changes 
of the shape of the irradiated breast, however, in accordance 
with our previous findings,3 the dose inhomogeneity within 
the target volume was higher in the prone position, which may 
be considered as a disadvantage of the technique. Similarly, 
despite the different dose-prescription strategy and the use of 
the field-in-field technique in the prone position only, worse 
homogeneity index values and larger maximum dose, indi-
cating greater dose inhomogeneity, were found in the prone 
position in the dosimetric study of Ramella et al.33
Conclusion
The radiation dose to the axillary and IM lymph nodes  during 
breast radiotherapy is therapeutically insufficient in most 
cases, and is lower in the prone than in the supine position. 
Table 3 Dosimetric values in the nodal regions in the prone and supine positions (P,0.001)
V25Gy, mean ± SE, % (range) V45Gy, mean ± SE, % (range) V47.5Gy, mean ± SE, % (range)
Prone Supine Prone Supine Prone Supine
level i 9.4±1.3 (0–58.9) 77.3±1.5 (35.1–99.9) 3.0±0.7 (0–39.8) 54.6±2.1 (0.8–97.5) 1.7±0.5 (0–31.7) 40.2±2.2 (0–94.2)
level ii 1.8±0.8 (0–64.2) 24.3±2.6 (0–99.8) 0.4±0.3 (0–28.4) 5.5±1.3 (0–69.0) 0.1±0.1 (0–14.1) 1.9±0.7 (0–49.8)
level iii 0.01±0.0 (0–1.5) 0.6±0.2 (0–17.1) 0 0 0 0
iM 4.9±1.1 (0–60.3) 25.5±2.6 (0–79.9) 0.1±0.1 (0–13.8) 4.9±0.9 (0–60.0) 0.1±0.1 (0–7.0) 2.5±0.7 (0–47.8)
Note: Doses to axillary levels I–III and the internal mammary (IM) lymph nodes were significantly lower in the prone position than in the supine position.
Abbreviation: se, standard error.
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Attention should be paid to the specif ic targeting of 
 lymph-node areas if this is clinically necessary.
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